TABLE 2.
Effect of FcγRI expression on other gp41-specific monoclonal Abs
| gp41 Aba | Epitope | 50% inhibitory dose (μg/ml)b in:
|
|
|---|---|---|---|
| TZM-bl cells | TZM-bl/FcγRI cells | ||
| 2F5 | MPER | >25 | 0.04 |
| 4E10 | MPER | >25 | 0.08 |
| M43 | Conformational | >25 | >25 |
| M47 | Conformational | >25 | >25 |
| 2.2B | Cluster II | >25 | >25 |
| 7B12 | Cluster I | >25 | >25 |
| 240-D | Cluster I | >3.8 | >3.8 |
| 246-D | Cluster I | >16.3 | >16.3 |
| F240 | Cluster I | >25 | >25 |
| 5F3 | Cluster I | >25 | >25 |
| 126-7 | Cluster I | >11.5 | >11.5 |
| 98.6 | Cluster II | >12.5 | 0.78 |
a
All Abs were subclass IgG1.
b
Neutralization of SHIV SF162P3 was assessed in parental TZM-bl cells and in TZM-bl cells that expressed FcγRI. Values are the concentration at which RLU were reduced 50% compared to those in virus control wells after subtraction of background RLU in cell control wells.